[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"surgical-wound-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:surgical-wound-infection":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,56,87,119,148,178,209,243,272,302,327,355],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100641421","preoperative-fasting-and-the-gut-microbiome-before-hip-replacement-100641421",false,"NCT07651462","Preoperative Fasting and the Gut Microbiome Before Hip Replacement","Preoperative Metabolic Optimization: Influence of Intermittent and Buchinger-Type Fasting on the Gut Microbiome, Immune Profile, and Postoperative Complications in Patients Undergoing Primary Total Hip Arthroplasty - A Randomized Controlled Trial","PreFAST-Hip","Inclusion Criteria:\n\n* Adults aged 18-75 years (inclusive)\n* Scheduled for elective primary total hip arthroplasty (THA)\n* Able and willing to provide written informed consent\n* Able to follow the 20-day preoperative fasting protocol independently at home (if randomized to the fasting arm) or willing to be randomized to either arm\n\nExclusion Criteria:\n\n* Resorption disorder due to bowel disease (e.g. inflammatory bowel disease, short-bowel syndrome, active celiac disease)\n* Antibiotic therapy within the last 2 months before baseline (T0)\n* Probiotic, prebiotic, or symbiotic supplementation within the last 2 months before baseline (T0)\n* Inability or unwillingness to provide informed consent\n* Severe comorbidity precluding fasting (e.g. ASA ≥ IV, advanced renal\u002Fhepatic impairment, eating disorder)\n* BMI \\\u003C 18.5 kg\u002Fm² (underweight)\n* Concurrent participation in another interventional drug or device trial\n* Pregnancy or breastfeeding","ALL","18 Years","75 Years",{"count":21,"type":22},130,"ESTIMATED","INTERVENTIONAL",[25],"NA","Postoperative complications occur in 5-15% of patients undergoing elective primary total hip arthroplasty (THA), including periprosthetic joint infection (PJI), thrombosis, wound healing disorders, and metabolic dysregulation. The gut microbiome and the systemic immune profile have both been implicated as modifiable contributors to perioperative complication risk. Preoperative therapeutic fasting has been shown to remodel the gut microbiome, lower proinflammatory cytokines, and improve metabolic parameters.\n\nThis single-center, prospective, randomized, two-arm controlled trial at Charité - Universitätsmedizin Berlin investigates whether a structured 20-day preoperative fasting intervention (alternating cycles of the Buchinger Fastenbox and intermittent fasting) modulates two co-primary endpoints - plasma IL-8 (a central proinflammatory marker) and gut microbial alpha-diversity (Shannon index) - compared with standard preoperative care. Secondary endpoints include further immune markers (TNFα, IL-10, T-\u002FB-\u002FNK-cell subsets, activation\u002Fexhaustion markers, monocyte HLA-DR), microbiome composition and function, continuous glucose-monitoring and daily metabolic measures, patient-reported outcomes (HOOS, PROMIS-33, infection self-report), and clinical outcomes (postoperative complications per EBJIS criteria, length of stay).\n\nAdults aged 18-75 undergoing elective primary THA are stratified by metabolic status (metabolically healthy vs. metabolically unhealthy according to harmonized metabolic-syndrome criteria) and randomized 1:1 to the fasting intervention versus standard care. Stool and whole-blood samples are collected at baseline (Day -21), and at Day +7 post-operatively for shotgun-metagenomic sequencing and multiparameter flow cytometry, with additional cytokine blood samples at Day -1 and 6 h \u002F 24 h \u002F 72 h post-operatively. Continuous glucose monitoring is performed in all participants from Day -21 until surgery. Planned enrollment is 130 participants.",[28,29,30,31,32],"Hip Osteoarthritis","Arthroplasty, Replacement, Hip","Postoperative Complications","Surgical Wound Infection","Gastrointestinal Microbiome",[34,35,36,37,38,39,40,41,42],"Therapeutic fasting","Buchinger fasting","Intermittent fasting","Gut microbiome","Immunophenotyping","Continuous glucose monitoring","Total hip arthroplasty","Metabolic syndrome","Preoperative optimization","RECRUITING","2026-06-17",{"date":46,"type":47},"2026-06-22","ACTUAL",{"date":49,"type":47},"2025-07-01",{"date":51,"type":22},"2026-12-31",{"name":53,"class":54},"Charite University, Berlin, Germany","OTHER",1,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":64,"targetDuration":4,"studyType":23,"phases":66,"briefSummary":67,"conditions":68,"keywords":72,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":55},"100633236","the-application-of-infrared-thermography-in-the-prediction-of-skin-healing-in-surgery-100633236","NCT07524062","The Application of Infrared Thermography in the Prediction of Skin Healing in Surgery","The Application of Infrared Thermography in the Prediction of Skin Healing in Surgery THERMS: THermography for Evaluation of Recovery and Monitoring of Surgical Wounds","THERMS","Inclusion Criteria:\n\n1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures\n2. Adult subjects (\\>18 years of age) at time of enrolment\n3. Patients undergoing a surgical excision under local anesthesia\n4. Indications of the excisions were skin lesions suspected to be malignant, skin lesions confirmed to be malignant via prior biopsy\n\nExclusion Criteria:\n\n1. Patient has history of pre-existing diabetes type I and II\n2. Patients with pre-existing chronic wound problems\n3. Patients with renal dysfunction,\n4. Patients with venous insufficiency confirmed via radiographic imaging\n5. Patients who received radiotherapy in the affected area in the past\n6. Patients with chronic steroid use in the past (\\> 3 months) or a immunosuppressant medication history\n7. Female who is pregnant",{"count":65,"type":22},120,[25],"This study investigates whether infrared thermography, a harmless and non-invasive thermal camera technique, can help monitor how surgical wounds heal after skin surgery. The goal is to detect wound problems earlier, such as infection or delayed healing, and to support doctors in making timely clinical decisions.",[69,31,30,70,71],"Wound Healing","Skin Neoplasms","Skin Transplantation",[73,74,75,76,77],"Infrared thermography","Surgical wound healing","Dermatosurgery","Thermal imaging","Wound complications","2026-06-16",{"date":80,"type":47},"2026-06-18",{"date":82,"type":47},"2026-06-15",{"date":84,"type":22},"2028-10",{"name":86,"class":54},"Universitaire Ziekenhuizen KU Leuven",{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":23,"phases":97,"briefSummary":98,"conditions":99,"keywords":108,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":55},"100596071","negative-pressure-wound-therapy-for-split-thickness-skin-grafting-to-the-lower-leg-after-excision-of-skin-tumour-a-multicentre-randomised-study-100596071","NCT07040683","Negative Pressure Wound Therapy for Split Thickness Skin Grafting to the Lower Leg After Excision of Skin Tumour: A Multicentre Randomised Study","Negative Pressure Wound Therapy for Split Thickness Skin Grafting to the Lower Leg After Excision of Skin Tumour: The Legs Trial - A Multicentre Randomised Study","LEGS","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Undergoing excision of a skin tumour on the lower leg with planned coverage using split-thickness skin grafting (STSG)\n* Eligible procedures include primary excision, secondary excision, or extended excision performed at the same site as a previous tumour surgery\n* Ability to provide written informed consent\n* Ability to comply with postoperative instructions and follow-up visits\n\nExclusion Criteria:\n\n* Inability to follow postoperative instructions due to cognitive impairment, dementia, or significant language barriers\n* Inability to provide informed consent\n* Severe systemic illness, including:\n* Ongoing sepsis\n* Advanced heart failure\n* End-stage renal or liver disease\n* Active chemotherapy within the previous three months\n* Ongoing treatment with immunosuppressive medications, including:\n* Systemic corticosteroids (e.g., prednisone \\>20 mg\u002Fday or equivalent)\n* Calcineurin inhibitors (e.g., cyclosporine, tacrolimus)\n* Antimetabolites (e.g., methotrexate, azathioprine, mycophenolate mofetil)\n* mTOR inhibitors (e.g., sirolimus, everolimus)\n* Biologic therapies (e.g., rituximab, TNF inhibitors, IL-6 inhibitors, IL-1, IL-17, IL-23 inhibitors)\n* Targeted molecular therapies (e.g., JAK inhibitors such as tofacitinib, baricitinib)\n* Other immunosuppressive drugs\n* Previous radiation therapy to the surgical site\n* Presence of severe skin disease affecting the planned graft recipient site (e.g., advanced psoriasis)",{"count":96,"type":22},242,[25],"The goal of this clinical trial is to compare the effect of negative pressure wound therapy (NPWT) versus traditional dressings on the incidence of transplant infection in adult patients undergoing split-thickness skin grafting (STSG) to the lower leg following excision of a skin tumour. The main questions it aims to answer are:\n\nDoes NPWT reduce the incidence of transplant infection within three months after STSG?\n\nDoes NPWT improve secondary outcomes such as graft take, reduce reoperations, complications, and resource use?\n\nResearchers will compare patients treated with NPWT to patients treated with traditional dressings to see if NPWT results in lower infection rates and better clinical outcomes.\n\nParticipants will:\n\nUndergo excision of a skin tumour on the lower leg followed by STSG.\n\nBe randomized to receive either NPWT or traditional dressings applied over the graft.\n\nFollow a structured postoperative care and mobilisation schedule.\n\nAttend follow-up visits at day 5 and day 14 postoperatively and be monitored through medical record review up to three months after surgery.",[71,100,101,102,30,31,103,104,105,69,106,107],"Skin Grafting","Split Thickness Skin Graft","Negative-Pressure Wound Therapy","Lower Extremity","Skin Cancer","Skin Tumour","Bandages","Leg",[71,100,109,102,30,31,103,69,106,107,70,104],"Split Thickness","2026-05-27",{"date":112,"type":47},"2026-05-28",{"date":114,"type":47},"2025-11-01",{"date":116,"type":22},"2030-03-31",{"name":118,"class":54},"Region Skane",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":126,"enrollmentInfo":127,"targetDuration":4,"studyType":23,"phases":129,"briefSummary":131,"conditions":132,"keywords":134,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":147},"100622135","phase-1-a-study-of-amicidin--topical-solution-for-patients-with-surgical-or-traumatic-wound-infections-100622135","NCT07379684","A Study of Amicidin-β Topical Solution for Patients With Surgical or Traumatic Wound Infections","A Phase 1 Study to Assess Safety and Tolerability of Amicidin-β Topical Solution in Adult Patients Undergoing Interventional Management of a Surgical or Traumatic Wound Infection","Main Inclusion Criteria:\n\n* Body Mass Index between 18.5 kg\u002Fsquare meter and 39.9kg\u002Fsquare meter\n* Surgical or traumatic wound determined by the Investigator to be infected within 90 days of surgery or trauma, with longest dimension between 3 and 15 cm. The diagnosis should include one or more of the following signs or symptoms:\n\n  * Purulent drainage\n  * Erythema\n  * Surrounding induration\n  * Fever or localized heat surrounding the wound\n  * Reported localized pain or localized tenderness on examination\n* Infected surgical or traumatic wound that is determined by the Investigator to required an interventional procedure, such as incision, drainage, irrigation, and\u002For debridement.\n* If female of childbearing potential, must have been practicing an acceptable method of birth control as judged by the Investigator for at least one month prior to enrollment.\n* Females of childbearing potential must agree that for the entire duration of the study (about 30 days), they will either practice true abstinence consistent with their preferred and usual lifestyle, or use double contraceptive methods.\n\nMain Exclusion Criteria:\n\nPatients with any of the following will be excluded:\n\n* Surgical or traumatic wound associated with surrounding cellulitis extending ≥10 cm from the wound edge\n* Confirmed necrotizing fasciitis or gangrenous ulcer\n* Multiple surgical or traumatic wound infections at different sites\n* Surgical or traumatic wound infection overlying bone fracture, with radiological evidence of non-union\n* Surgical or traumatic wound infection with open peritoneal cavity\n* Surgical or traumatic wound infection extending to an organ space\n* Surgical or traumatic wound infection extending to implanted surgical hardware or protesis. Note: surgical drains and packing are permitted\n* Surgical or traumatic wound infection involving head and neck\n* Surgical or traumatic wound infection involving burn injury\n* Suspected or confirmed osteomyelitis or septic arthritis\n* Surgical or traumatic wound infection known or suspected to be caused by fungal or mycobacterial organisms\n* Wound with diagnosis of neuropathic or diabetic foot ulcer or a previous diagnosis of moderate to severe chronic venous insufficiency of a lower extremity in patients with an infected surgical to traumatic wound of the lower extremity\n* Wound due to malignancy\n* Antibiotic therapy for an infection other than the surgical or traumatic wound infection\n* Patient requires supplemental O2 or mechanical ventilation\n* Pulse Oximetry (SpO2) reading of ≤ 92% on room air (confirmed by two additional readings ≤92% over 15 min). At geographic locations of high altitude, a lower SpO2 limit (e.g., ≤ 91%) may be used at Investigator's discretion","79 Years",{"count":128,"type":22},44,[130],"PHASE1","The goal of this Phase 1 clinical trial is to learn about the safety profile of Amicidin-β topical solution applied directly into infected surgical or traumatic wounds during a surgical procedure. The main questions it aims to answer are:\n\n1. Is Amicidin-β topical solution safe to test in larger clinical trials?\n2. Is Amicidin-β topical solution absorbed into the bloodstream from local wound application?\n3. Is Amicidin-β topical solution easy for the surgeon to use? Participants will receive either standard of care alone, or standard of care with intrawound Amicidin-β topical solution for the management of their wound infection. Researchers will compare these two groups (standard of care alone to standard of care with Amicidin-β topical solution) to see if there are any study drug-related adverse effects.",[31,133],"Traumatic Wound Infection",[135,136],"Surgical wound infection","Traumatic wound infection","2026-05-05",{"date":139,"type":47},"2026-05-06",{"date":141,"type":22},"2026-05-31",{"date":143,"type":22},"2027-02-28",{"name":145,"class":146},"Macro Biologics, Inc.","INDUSTRY",4,{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":23,"phases":157,"briefSummary":158,"conditions":159,"keywords":162,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":55},"100622388","safety-and-efficacy-of-ntp-in-thyroid-surgery-pilot-study-on-morbidity-prevention-and-adjuvant-oncological-control-100622388","NCT07382973","Safety and Efficacy of NTP in Thyroid Surgery: Pilot Study on Morbidity Prevention and Adjuvant Oncological Control","Evaluation of Non-Thermal Plasma as an Innovative Strategy for Optimizing Post-Surgical Wound Treatment in Patients of Thyroid Surgery: An Ethical and Clinical Approach","Inclusion Criteria:\n\n* Patients aged 18 years or older.\n* Diagnosis of thyroid pathology requiring total or subtotal thyroidectomy.\n* Signed Informed Consent Form (ICF).\n* Patients capable of complying with the 12-week follow-up schedule.\n\nExclusion Criteria:\n\n* History of previous neck surgery or radiation therapy in the cervical area.\n* Known history of keloid formation or hypertrophic scarring.\n* Presence of active systemic or local infection at the time of surgery.\n* Patients with implanted electronic devices (e.g., pacemakers or defibrillators) due to the use of RF-based plasma.\n* Pregnancy or breastfeeding.\n* Concurrent use of systemic corticosteroids or immunosuppressive drugs that may impair wound healing.",{"count":156,"type":22},26,[25],"The goal of this clinical trial is to evaluate the therapeutic efficacy and safety of non-thermal plasma (NTP) as an adjuvant treatment for surgical bed decontamination and accelerated tissue repair in patients undergoing total thyroidectomy. The study aims to address the following objectives:\n\n* Does the intraoperative application of NTP to the surgical bed and closed incision promote accelerated tissue regeneration compared to conventional postoperative care?\n* Does NTP treatment reduce postoperative inflammatory response, pain intensity, and the incidence of site-specific complications (such as surgical site infection or seroma)?\n* What is the safety profile of helium-based NTP in the cervical anatomical region regarding neighboring neurovascular structures?\n\nParticipants will be randomized into two arms:\n\n1. The experimental group: Receiving a standardized application of helium-based NTP (at a frequency of 13.56 MHz) to the surgical bed prior to closure and subsequently to the sutured incision.\n2. The control group: Receiving standard-of-care surgical wound management.\n\nClinical follow-up will include quantitative assessment of healing rates, pain scales (VAS), and biochemical or clinical markers of inflammation at scheduled intervals (Days 1, 7, 15, and up to 12 weeks post-surgery).",[160,69,161,31],"Thyroid Diseases","Thyroidectomy",[163,164,165,69,166,167,168],"Non-Thermal Plasma","Cold Plasma","Thyroid Surgery","Postoperative Pain","Adjuvant Therapy","Surgical Bed Decontamination","2026-02-05",{"date":171,"type":47},"2026-02-09",{"date":173,"type":47},"2025-08-20",{"date":175,"type":22},"2026-12-30",{"name":177,"class":54},"National Institute of Nuclear Research - Mexico",{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":23,"phases":187,"briefSummary":189,"conditions":190,"keywords":191,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":55},"100603891","phase-3-the-effect-of-bacterial-decolonization-before-skin-cancer-surgery-on-infection-rate-of-lower-extremity-wounds-left-open-to-heal-100603891","NCT07142408","The Effect of Bacterial Decolonization Before Skin Cancer Surgery on Infection Rate of Lower Extremity Wounds Left Open to Heal","The Effect of Pre-Operative Bacterial Decolonization on Post-Operative Infection Rate for Lower Extremity Wounds Healing by Second Intention","Inclusion Criteria:\n\n* Age at least 18 years old\n* Scheduled to undergo surgical treatment for skin cancer on the lower extremities and have no other surgeries scheduled in the coming weeks after the procedure\n* Will have a surgical wound that will be left open to heal by secondary intention\n\nExclusion Criteria:\n\n* Age under 18 years old\n* Have a known allergy to chlorhexidine or mupirocin\n* Have a history of Staphylococcus aureus infection\n* Have a history of heart valve or joint replacement surgery requiring pre-operative antibiotics",{"count":186,"type":22},848,[188],"PHASE3","The goal of this clinical trial is to learn if reducing bacterial load on the skin and nostrils with topical antibacterial soap and ointment, respectively, reduces rate of infection in surgical sites on lower leg wounds left open to heal in adults undergoing skin cancer surgery.\n\nThe main question it aims to answer is:\n\nDoes Hibiclens antibacterial skin cleanser and mupirocin antibacterial ointment applied to nostrils prior to surgery lower the number of times participants develop an infection in their open wound on the lower leg?\n\nResearchers will compare the treatment group to the standard of care, which involves no treatment prior to surgery, to see if topical antibiotics applied prior to surgery affect infection rates between the two groups.\n\nParticipants randomized to the treatment group will:\n\nShower with Hibiclens once daily for 5 days prior to the day of surgery and apply mupirocin to the nostrils twice daily for 5 days prior to the day of surgery. They will then send pictures of their surgical site to monitor for signs of infection at 2-week and 4-week post-operation.\n\nParticipants randomized to the control group (standard of care) will:\n\nNOT apply the topical antibacterials prior to the day of surgery. They will then send pictures of their surgical site to monitor for signs of infection at 2-week intervals for 1 month after surgery.",[31],[192,193,194,195,196,197,69,198,199],"Lower Extremity Wound","Skin Cancer Surgery","Infection Rate","Prophylactic Topical Antibiotics","Chlorhexidine","Mupirocin","Secondary Intention","Infection Prevention","2025-08-22",{"date":202,"type":47},"2025-08-26",{"date":204,"type":47},"2023-03-13",{"date":206,"type":22},"2030-12",{"name":208,"class":54},"The Cooper Health System",{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":215,"eligibilityCriteria":216,"healthyVolunteers":11,"sex":17,"minAge":217,"maxAge":218,"enrollmentInfo":219,"targetDuration":4,"studyType":23,"phases":221,"briefSummary":222,"conditions":223,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":242},"100382220","phase-3-perioperative-respiratory-care-and-outcomes-for-patients-undergoing-high-risk-abdominal-surgery-100382220","NCT04256798","Perioperative Respiratory Care and Outcomes for Patients Undergoing High Risk Abdominal Surgery","PErioperative Respiratory Care and Outcomes for patieNts Undergoing hIgh Risk abdomiNal Surgery: A 2x2 Factorial, International Pragmatic Randomised Controlled Trial Across Low and Middle-income Countries","PENGUIN","Inclusion Criteria:\n\n* Adults and children aged 10 years or over\n* Elective or emergency abdominal surgery via midline laparotomy with an anticipated abdominal incision of at least 5cm in length\n* Written informed consent of patient (signature or a fingerprint)\n\nExclusion Criteria:\n\n* Patients undergoing caesarean section\n* Patients with a documented or suspected allergy to chlorhexidine\n* Patient unable to complete postoperative follow-up (not contactable after discharge)\n* Previous enrolment in PENGUIN within the past 30 days\n* American Society of Anesthesiologists (ASA) grade V patients (expected to die with or without surgery)","10 Years","100 Years",{"count":220,"type":22},12942,[188],"PENGUIN is a pragmatic multi-center trial investigating the effects of pre-operative mouthwash and perioperative oxygen on the incidences of pneumonia and surgical site infection (SSI) following major abdominal surgery.\n\nPatients will be recruited from low and middle income countries and randomly assigned to a trial treatment arms: a) pre-operative chlorhexidine mouthwash and 80-100% FiO2; b) no pre-operative mouthwash and 80-100% fraction of inspired oxygen (FiO2); c) pre-operative chlorhexidine mouthwash and 21- 30% FiO2; or d) no pre-operative mouthwash and 21-30% FiO2.",[224,225,226,227,31,30,228,229,230,231,196,232],"Infection","Pneumonia","Surgical Site Infection","Wound Infection","Anesthesia","Communicable Disease","Pathologic Processes","Perioperative Complication","Laparotomy","2025-02-18",{"date":235,"type":47},"2025-02-19",{"date":237,"type":47},"2020-11-13",{"date":239,"type":22},"2026-06-01",{"name":241,"class":54},"University of Birmingham",37,{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":249,"eligibilityCriteria":250,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":251,"targetDuration":4,"studyType":23,"phases":253,"briefSummary":255,"conditions":256,"keywords":257,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":271},"100575395","phase-2-multicenter-study-protocol-research-on-evaluation-and-detection-of-surgical-wound-complications-with-ai-based-recognition-redscar-trial-100575395","NCT06771726","Multicenter Study Protocol: Research on Evaluation and Detection of Surgical Wound Complications with AI-based Recognition. (REDSCAR-trial)","Multicenter Study Protocol: Research on Evaluation and Detec-tion of Surgical Wound Complications with AI-based Recogni-tion. (REDSCAR-trial)","REDSCAR","Inclusion Criteria:\n\n* Participants must have signed an informed consent.\n* Participants must be over 18 years of age.\n* Participants must have undergone either urgent or scheduled surgery performed via laparotomy or laparoscopy.\n* Participants need access to a smartphone capable of downloading the app with android OS.\n* Either the participant or a close family member must be able to operate the app effectively.\n* Participants must be able to attend follow-up consultations at the surgical outpatient clinic after discharge, one week post-surgery, or earlier if the app flags a potential infection.\n\nExclusion Criteria:\n\n* Patients who lack access to a smartphone or are unable to properly use the app.\n* Patients unfamiliar with mobile devices or unable to comprehend the app's functionality or questions.\n* Patients who did not provide informed consent.\n* Patients who are unable to comply with the follow-up requirements.",{"count":252,"type":22},168,[254,188],"PHASE2","The increasing use of telemedicine in surgical care has demonstrated significant poten-tial for improving patient outcomes and optimizing healthcare resources. This study investigates the efficacy of the RedScar© app in telematic detection and monitoring of surgical site infections (SSIs), a major cause of healthcare-associated infections (HAIs) with significant economic and health impacts. RedScar© leverages a patient's smartphone to provide automated infection risk assessments without requiring clini-cian input, offering a potential solution for remote postoperative care. In a pilot study, RedScar© demonstrated 100% sensitivity and 83.13% specificity in detecting SSIs, with high patient satisfaction regarding its comfort, cost-effectiveness, and ability to reduce absenteeism. This multicenter prospective study aims to validate these findings, com-paring app-based detection with in-person evaluations. Primary objectives include as-sessing the sensitivity and specificity of RedScar© using receiver operating character-istic (ROC) analysis, while secondary objectives include evaluating patient satisfaction and standardizing telematic follow-up across centers. The study will include 168 pa-tients undergoing abdominal surgery, with follow-up assessments conducted remotely via the app and in-person at specified intervals. Data will be analysed using descrip-tive and statistical methods to assess diagnostic accuracy and patient satisfaction. This research seeks to further develop RedScar© as a reliable, scalable tool for enhancing postoperative care, reducing healthcare costs, and improving patient experiences in surgical recovery.",[31],[258,259,260,261],"surgical wound infection","Telemedicine","smartphone application","artificial intelligence","2025-01-16",{"date":264,"type":47},"2025-01-20",{"date":266,"type":47},"2024-01-01",{"date":268,"type":22},"2025-12",{"name":270,"class":54},"Universitat de les Illes Balears",5,{"id":273,"slug":274,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":278,"eligibilityCriteria":279,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":280,"targetDuration":4,"studyType":23,"phases":282,"briefSummary":283,"conditions":284,"keywords":288,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":300,"locationsCount":55},"100530774","cosmetic-outcome-of-electrocautery-scalpel-and-peak-plasmablade-for-surgical-breast-incisions-100530774","NCT06191159","Cosmetic Outcome of Electrocautery, Scalpel and PEAK PlasmaBlade for Surgical Breast Incisions","A Randomized Controlled Trial Comparing the Cosmetic Outcome of Electrocautery, Scalpel and PEAK PlasmaBlade for Surgical Breast Incisions","SCPPB","Inclusion Criteria:\n\n* Patients having a total mastectomy with or without axilla surgical staging\n\nExclusion Criteria:\n\n* Patients having immediate breast reconstruction\n* Patients with a diagnosis of inflammatory breast cancer\n* History of keloid scar formation\n* History of connective tissue disorder (scleroderma or rheumatoid arthritis with skin involvement)\n* Patients with prior incision at the planned mastectomy site.\n* Patients with known suture hypersensitivity\n* Patients with evidence of current infection",{"count":281,"type":22},186,[25],"This study will compare the cosmetic scar result from the use of scalpel, electrocautery, and pulsed electron avalanche knife (PEAK) PlasmaBlade (PPB) for the initial skin incision for total mastectomy procedures without immediate breast reconstruction.\n\nIt is hypothesized that there will be no significant difference in mastectomy scar cosmesis.\n\nThe purpose and objectives of this study are:\n\n1. To evaluate and compare the cosmetic scar result from the use of scalpel, standard electrocautery, or PEAK PlasmaBlade for initial incision for total mastectomy procedures without immediate breast reconstruction.\n2. To inform future equipment choices for breast surgery including potential elimination of scalpels and their attendant risks.",[285,31,286,30,287],"Wound Complication","Post-operative Pain","Scar",[289,290,291,292,293],"Electrocautery","PEAK PlasmaBlade","Scalpel","Mastectomy","Incision","2024-12-10",{"date":296,"type":47},"2024-12-16",{"date":298,"type":47},"2024-12-09",{"date":268,"type":22},{"name":301,"class":54},"University of British Columbia",{"id":303,"slug":304,"hasResults":11,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":308,"eligibilityCriteria":309,"healthyVolunteers":310,"sex":17,"minAge":311,"maxAge":4,"enrollmentInfo":312,"targetDuration":4,"studyType":23,"phases":314,"briefSummary":315,"conditions":316,"keywords":4,"overallStatus":317,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":55},"100521355","closed-incision-negative-pressure-wound-therapy-for-the-prevention-of-surgical-site-infections-in-abdominal-surgery-100521355","NCT06068517","Closed Incision Negative Pressure Wound Therapy for the Prevention of Surgical Site Infections in Abdominal Surgery","Closed Incision Negative Pressure Wound Therapy for the Prevention of Surgical Site Infections in Abdominal Surgery - A Multicenter Randomized Controlled Trial","CISSI","Inclusion Criteria:\n\n* Elective or emergency laparotomy, or laparoscopy converted to laparotomy, including surgery for complications after elective operations\n* Incision length ≥ 10 cm\n* Centers for Disease Control and Prevention (CDC) wound class 1 and 2 (clean, clean-contaminated)\n* Abdominal closure with or without mesh implantation\n* Primary abdominal closure or closure after open abdomen treatment\n* Age over 18 years\n* Written informed consent\n\nExclusion Criteria:\n\n* Age ≤ 18 years\n* CDC wound class 4 (dirty\u002Finfected wound)\n* Organ transplantation\n* Sensitivity or allergy to silver",true,"19 Years",{"count":313,"type":22},654,[25],"Surgical site infections (SSI) are a frequent complication in abdominal surgery. SSI lead to worse outcomes for the affected patients and significantly higher healthcare costs. Closed incision negative pressure wound therapy (ciNPWT) consists of a non-invasive, vacuum-assisted system that applies negative pressure to closed surgical incisions. It is currently unclear, if ciNPWT reduces SSI in patients undergoing abdominal surgery. This trial will investigate the effect of ciNPWT on SSI in abdominal surgery.",[31],"NOT_YET_RECRUITING","2024-12-04",{"date":320,"type":47},"2024-12-05",{"date":322,"type":22},"2026-03-01",{"date":324,"type":22},"2028-05-31",{"name":326,"class":54},"Insel Gruppe AG, University Hospital Bern",{"id":328,"slug":329,"hasResults":11,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":4,"eligibilityCriteria":333,"healthyVolunteers":310,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":334,"targetDuration":4,"studyType":23,"phases":336,"briefSummary":337,"conditions":338,"keywords":342,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":55},"100548433","surgical-handwashing-drying-with-one-or-two-surgical-towels-100548433","NCT06420934","Surgical Handwashing: Drying With One or Two Surgical Towels","Comparison of the Breach of the Aseptic Barrier After Surgical Handwashing: Drying With One or Two Surgical Towels","Inclusion Criteria:\n\n* Workers and students who have a current affiliation with the institutions where the study will be executed.\n* Workers and students whose practice or work involves performing surgical handwashing at least once a week for invasive procedures.\n\nExclusion Criteria:\n\n* Workers and students who do not wish to participate in the study.\n* Workers and students whose work activities do not allow them time to participate in the study.\n* Workers and students who are allergic to the fluorescent cream\n* Workers and students whose nails exceed a length of 0.5 cm from the fingertip edge.\n* Workers and students whose nails are painted with polish.\n* Workers and students who refuse to remove jewelry and accessories from wrists and hands.\n* Workers and students with recent wounds on hands or forearms, including tattoos done in the last month.\n* Workers and students who do not adhere to the handwashing and drying technique taught prior to the study's implementation.",{"count":335,"type":22},72,[25],"This study aims to determine whether the use of two sterile towels for drying after surgical handwashing results in fewer contamination events compared to the use of only one towel among healthcare personnel. This randomized, multicenter, superiority-controlled trial will enroll up to 72 healthcare workers and surgical residents from three hospitals in Bogotá, Colombia. A fluorescent product will simulate bacteria, and contamination will be assessed by evaluating the presence of fluorescent cream after hand drying technique with either two or one surgical sterile towel. Data will be collected through REDCap and deidentified. Differences in the proportion of contamination between the two groups will be assessed using an exact Fischer test, and confounding variables will be included in the analysis through logistic multivariate regression, with a significance level set a priori at 0.05. Results will be submitted for publication in a peer-reviewed journal.",[339,31,340,341],"Hand Hygiene","Healthcare Associated Infection","Medical Errors",[343,344,345,340,339],"Surgical Scrubbing","Handwashing","Disinfection","2024-10-01",{"date":348,"type":47},"2024-10-02",{"date":350,"type":47},"2024-04-26",{"date":352,"type":22},"2025-06-30",{"name":354,"class":54},"Instituto de Ortopedia Infantil Roosevelt",{"id":356,"slug":357,"hasResults":11,"nctId":358,"briefTitle":359,"officialTitle":360,"acronym":361,"eligibilityCriteria":362,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":363,"enrollmentInfo":364,"targetDuration":4,"studyType":23,"phases":366,"briefSummary":367,"conditions":368,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":371,"startDateStruct":373,"completionDateStruct":375,"leadSponsor":377,"locationsCount":55},"100431606","reducing-intraoperative-eskape-transmission-through-use-of-a-personal-hand-hygiene-system-100431606","NCT04900298","Reducing Intraoperative ESKAPE Transmission Through Use of a Personal Hand Hygiene System","Reducing Intraoperative ESKAPE (Enterococcus, S. Aureus, Klebsiella, Acinetobacter, Pseudomonas, and Enterobacter Spp.) Transmission in the Adult Operating Room Via Use of a Personal Hand Hygiene System Optimized by OR PathTrac","ESKAPE","Patient Inclusion Criteria:\n\nPatients ≥ 18 years of age having surgery in an adult operating suite at the research center involving the following specialties: orthopedics\u002Fspine, orthopedics\u002Ftotal joint, gynecology\u002Foncology, colorectal, open vascular, and open urological, general abdominal, acute care, cardiothoracic, and plastic\u002Fbreast.\n\nPatient Exclusion Criteria:\n\n* Patients with a known infection at the time of surgery.\n* Prisoners\n* Pregnant Women\n* Patients lacking capacity to consent\n* Patients with an allergy to a component of hand hygiene solution, such as ethyl alcohol\n* Refusal of consent\n\nAnesthesia Provider Inclusion Criteria:\n\n• Faculty physicians, resident physicians, or certified registered nurse anesthetists that provide care for adults having surgery at the research center.\n\nAnesthesia Provider Exclusion Criteria:\n\n* Refusal of consent\n* Open sores of the hands\n* Known skin infection","99 Years",{"count":365,"type":22},40,[25],"The investigators hypothesize that the use of a personal hand hygiene system (SafeHavenTM) by anesthesia providers in the adult operating room, combined with a novel infectious pathogen tracking system (OR PathTrac) will decrease participant exposure to pathologic bacteria in the adult operating room.",[31,369],"Cross Infection","2024-06-18",{"date":372,"type":47},"2024-06-21",{"date":374,"type":47},"2022-01-01",{"date":376,"type":22},"2026-06-30",{"name":378,"class":54},"Oregon Health and Science University"]